Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study.
Philip A PhilipVaibhav SahaiNathan BaharyAmit MahipalAnup Kasi Loknath KumarCaio Max S Rocha LimaAngela T AlistarPaul E ObersteinTalia GolanJean-Phillippe MetgesJill LacyChristos FountzilasCharles D LopezMichel DucreuxPascal HammelMohamed E SalemDavid BajorAl Bowen BensonSanjeev LutherTimothy PardeeEric Van CutsemPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Devimistat in combination with mFFX did not improve long- and short-term mPC patient outcomes compared with standard FFX. There were no new toxicity signals with the addition of devimistat.